<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962922</url>
  </required_header>
  <id_info>
    <org_study_id>LCP-Tacro 3004</org_study_id>
    <nct_id>NCT01962922</nct_id>
  </id_info>
  <brief_title>Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.</brief_title>
  <official_title>Prospective, Rand, Open-label, Single-center, 2 Sequence, 3 Period Crossover Study to Compare the Steady State PK of Once-Daily-Extended Release LCP-Tacro to Generic Tacrolimus Capsules Twice Daily in Stable A A Renal Transplant pt.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloxis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, prospective, single-center, randomized, two sequence, three period crossover
      study to compare the steady state pharmacokinetics of LCP-Tacro tables to generic tacrolimus
      capsules administered twice daily in stable African-American renal transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is open label, prospective, single-center, randomized, two sequence, three period
      crossover study to compare the steady state pharmacokinetics of once daily dosing of
      LCP-Tacro tablets to tacrolimus capsules administered twice daily in stable African American
      kidney transplant patients.

      Approximately 72 male and female African American renal transplant patients on table
      immunosuppression regimens will be randomly assigned in a 1:1 ratio to one of two sequences:

      Sequence 1: (n=36) 18 patients requiring less than 0.15 mg/kg/day and 18 patients requiring
      equal to or greater than 0.15 mg/kg/day. Patients will continue on generic tacrolimus
      capsules on days 1-7 (24 hours PK profile on day 7) then patients are switched to LCP-Tacro
      tablets (at 15% lower dose of twice daily generic tacrolimus) on day 8.

      Sequence 2: (n=36) 18 patients requiring less than 0.15 mg/kg/day and 18 patients requiring
      equal to or greater than 0.15 mg/kg/day. Patients will receive LCP-Tacro tablets (at 15%
      lower dose than generic tacrolimus twice daily formulation) on days 1-7 (24 hour PK profile
      on day 7) patients are switched back to twice daily generic tacrolimus treatment beginning on
      day 8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 7</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of C(Max) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 7</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of C(Min) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 7</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 14</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of C(Max) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 14</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of C(Min) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 14</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 21</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of C(Max) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 21</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of C(Min) for Envarsus XR and IR-Tac</measure>
    <time_frame>Day 21</time_frame>
    <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>LCP-Tacro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Envarsus XR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus - IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCP-Tacro</intervention_name>
    <description>once-daily extended release tablet</description>
    <arm_group_label>LCP-Tacro</arm_group_label>
    <other_name>Envarsus XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus -IR</intervention_name>
    <description>twice daily capsules</description>
    <arm_group_label>Tacrolimus - IR</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Astagraf</other_name>
    <other_name>Generic Tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥18-80 old, male or female

          -  African Americans

          -  Willing to give written informed consent and to comply with study visits and
             restrictions, including being able to speak, write and understand English

          -  Pt who have received a primary or secondary transplant

          -  Pt least 6 (six) mth post-transplant and on a stable dose of tacrolimus

          -  BMI ≥19

          -  Pt who are sero-positive for Hepatitis B or C positive may also be enrolled

          -  Pt maintained on concurrent immunosuppression with stable doses during screening

          -  Pt on a proton PPI remain on the same PPI formulation and dose during the PK portion
             of the study.

          -  During PK phase Only: Pt taking any medication that could interfere with tacrolimus
             blood levels, including prescription and over-the-counter medications, herbal or food
             supplements (including grapefruit, and pomegranate products), or medications must
             continue the same dose and are willing to continue the same dose/routine

          -  During PK phase Only: the patient is not scheduled to begin any new medication that
             could interfere with tacrolimus blood levels, including prescription and
             over-the-counter medications, herbal or food

        Exclusion Criteria:

          -  Evidence of acute rejection episode within the past three months

          -  Pt not Africa-American

          -  Recipients of organ transplants other than kidney

          -  Known to be HIV positive at transplant

          -  Pt with recurrent focal segmental glomerulosclerosis (FSGS)

          -  Pt with any severe medical condition (including infection) requiring acute or chronic
             treatment

          -  Pt with a positive DSA

          -  Pt with a positive BK virus results

          -  GFR &lt; 25 ml/min measured by MDRD4 as SOC within last 30 days

          -  Patients with AST, ALT, total bilirubin &gt; 2.5 x ULN or evidence of severe liver
             disease

          -  Pt with WBC &lt; to 2000/mm3 or ANC &lt; to 1500 mm3 with PLT &lt; 75,000/mm3 or HGB &lt; 8 g/dl

          -  Pt with mental or physical conditions or known non-adherence

          -  Presence of intractable immunosuppressant complications of side effects resulting in
             dose adjustment of tacrolimus

          -  Exposed to investigational therapy within 30 days prior to enrollment

          -  No anticipated changes in the immunosuppressive regimen, other than those specified by
             the study protocol

          -  Pt with severe diabetic gastroparesis or other severe GI disturbances

          -  Pt who have underwent gastric banding or gastric bypass at any time pre or
             post-transplant

          -  Pregnant or nursing (lactating) women, or planning to become pregnant

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant who are unwilling to use a defined SOC of method
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Callahan, RN</last_name>
    <role>Study Director</role>
    <affiliation>Veloxis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washingto University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <results_first_submitted>February 23, 2016</results_first_submitted>
  <results_first_submitted_qc>July 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2016</results_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>25 November 2013 (first patient enrolled) to 09-Mar-2015 (last patient completed initial pharmacokinetics [PK] portion of the study, the ‘PK Cross-over’ period), approximately 16 months enrolled from 3 US medical centers:University of Pennsylvania;University of Illinois at Chicago;Washington School of Medicine</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>•Sequence I: (n=27) Patients will continue on twice-daily IR-Tac capsules on Days 1–7 (24-hour PK profile on Day 7), then patients are switched to Envarsus XR tablets (at a dose 15% lower than their Tac - IR doses) on Day 8. PK on day 14 and 21.
Patients in sequence 1 are on Envarsus XR at Day 21. Patient may continue on extension up to a total of 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>• Sequence II: (n=23) 1 Patients receive Envarsus XR tablets (at 15% lower dose than their IR-Tac dose) on Days 1–7 (24-hour PK profile on Day 7), then patients are switched back to twice-daily Tac - IR treatment beginning on Day 8. PK on days 14 and 21.
Patients in sequence 2 are on Tac - IR at Day 21. Patient have option of continuing in extension portion of the study on Tac - IR for up to 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PK Portion Day 7</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>PK Portion Day 14</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>PK Portion Day 21</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extendion Portion (up to Month 6)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>no longer wished to participate in study</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence I</title>
          <description>Sequence I IR-Tac→Envarsus XR (N = 27)</description>
        </group>
        <group group_id="B2">
          <title>Sequence II</title>
          <description>Sequence II Envarsus XR→IR-Tac (N = 23)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
        <time_frame>Day 7</time_frame>
        <population>For this outcome measure the PK population N=46 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
          <population>For this outcome measure the PK population N=46 was used.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.9" spread="77.78"/>
                    <measurement group_id="O2" value="247.9" spread="102.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of C(Max) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
        <time_frame>Day 7</time_frame>
        <population>For this outcome measuure the Protocol PK population of N = 46 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of C(Max) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
          <population>For this outcome measuure the Protocol PK population of N = 46 was used.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.53" spread="5.464"/>
                    <measurement group_id="O2" value="26.84" spread="13.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of C(Min) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
        <time_frame>Day 7</time_frame>
        <population>For this outcome measure the Protocol PK population N= 46 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of C(Min) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
          <population>For this outcome measure the Protocol PK population N= 46 was used.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="2.487"/>
                    <measurement group_id="O2" value="7.06" spread="2.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
        <time_frame>Day 14</time_frame>
        <population>For this outcome measure the PK population N=46 was used</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
          <population>For this outcome measure the PK population N=46 was used</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.3" spread="124.40"/>
                    <measurement group_id="O2" value="225.7" spread="56.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of C(Max) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
        <time_frame>Day 14</time_frame>
        <population>For this outcome measuure the Protocol PK population of N = 46 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of C(Max) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
          <population>For this outcome measuure the Protocol PK population of N = 46 was used.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.83" spread="9.265"/>
                    <measurement group_id="O2" value="26.31" spread="13.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of C(Min) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours</description>
        <time_frame>Day 14</time_frame>
        <population>For this outcome measuure the Protocol PK population N= 46 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of C(Min) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours</description>
          <population>For this outcome measuure the Protocol PK population N= 46 was used.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.34" spread="3.769"/>
                    <measurement group_id="O2" value="6.46" spread="1.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
        <time_frame>Day 21</time_frame>
        <population>For this outcome measure the PK population N=46 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of AUC(0-24) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
          <population>For this outcome measure the PK population N=46 was used.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.3" spread="111.79"/>
                    <measurement group_id="O2" value="230.3" spread="53.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of C(Max) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
        <time_frame>Day 21</time_frame>
        <population>For this outcome measuure the Protocol PK population of N = 46 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of C(Max) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate C(max). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
          <population>For this outcome measuure the Protocol PK population of N = 46 was used.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.71" spread="8.387"/>
                    <measurement group_id="O2" value="26.31" spread="7.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of C(Min) for Envarsus XR and IR-Tac</title>
        <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
        <time_frame>Day 21</time_frame>
        <population>For this outcome measure the Protocol PK population N= 46 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Envarsus XR</title>
            <description>Tacrolimus tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus - IR</title>
            <description>Tacrolimus capsules twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of C(Min) for Envarsus XR and IR-Tac</title>
          <description>Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling time was used to calculate AUC(0-24). Arithmetic mean and standard deviation is given below.
Nominal time points used were: Pre-dose (C0) and then 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 13, 14, 16, 18 and 24 hours.</description>
          <population>For this outcome measure the Protocol PK population N= 46 was used.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" spread="3.281"/>
                    <measurement group_id="O2" value="6.62" spread="1.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from start of first dose of study medication, through and including last dose of study medication during the up to 6 month extension period.</time_frame>
      <desc>Adverse events are associated with the treatment the patient is on at the onset date of the adverse event and not the portion of the study (e.g. PK or extention portion). The below figures are cumulative for the entire study participation start of study through 6 month extension.</desc>
      <group_list>
        <group group_id="E1">
          <title>Envarsus XR</title>
          <description>Tacrolimus extended release</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus - IR</title>
          <description>brand IR tacrolimus</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has no objection to publication of the results of the Study by Site based on information collected or generated by Site; provided, however, that such publication must not precede the primary manuscript (unless no such multi-site publication is completed within twelve (12) months following the completion of the Study or unless Sponsor notifies Site in writing that no such multi­ center publication shall be made).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leslie Callahan</name_or_title>
      <organization>Veloxis Pharmaceutical</organization>
      <phone>732-321-3221</phone>
      <email>lca@veloxis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

